Mitochondrial Genome Maintenance Protein (G92667)

Target Name: MGME1

NCBI ID: G92667

MGME1

Mitochondrial Genome Maintenance Protein

Mitochondrial genome maintenance exonuclease 1 (MGME1) is a protein that plays a crucial role in maintaining the integrity of the mitochondrial genome. Mitochondria are organelles found in the cells that power our bodies, and they are responsible for generating the energy we need for daily life. The mitochondrial genome is a separate DNA molecule that contains the instructions for building and maintaining the mitochondria. MGME1 is essential for the proper function and survival of the mitochondria.

MGME1 functions as an enzyme that helps to remove damaged or unnecessary DNA from the mitochondrial genome. It does this by using a process called exonuclease, which means it breaks down the DNA into smaller pieces. This helps to ensure that the mitochondrial genome remains stable and free from errors. MGME1 is also involved in the repair of damaged DNA, which is essential for maintaining the integrity of the mitochondrial genome.

MGME1 is a protein that is expressed in most tissues and cells of the body. It is primarily located in the mitochondria, but it can also be found in other cells, such as the liver and the skeletal muscle. MGME1 is a pro-secretory protein, which means it is produced in the cytoplasm and then released into the extracellular space. It can also be found in different forms such as cytoplasmic protein, soluble protein, and membrane protein.

MGME1 has been shown to be involved in a number of different cellular processes in the body. For example, it is involved in the regulation of mitochondrial dynamics, which is important for the proper functioning of the mitochondria. MGME1 is also involved in the regulation of mitochondrial DNA replication, which is essential for the maintenance of the mitochondrial genome.

MGME1 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of a variety of diseases. For example, studies have shown that MGME1 is involved in the development of cancer, and that it can serve as a potential drug target. MGME1 has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

MGME1 is also a potential biomarker for a variety of diseases. For example, studies have shown that MGME1 is involved in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the diagnosis of certain metabolic disorders, such as diabetes.

In conclusion, MGME1 is a protein that plays a crucial role in maintaining the integrity of the mitochondrial genome. It is essential for the proper function and survival of the mitochondria, and it is involved in a number of different cellular processes that are important for the development and progression of a variety of diseases. As a result, MGME1 is a potential drug target and a potential biomarker for a variety of diseases.

Protein Name: Mitochondrial Genome Maintenance Exonuclease 1

Functions: Metal-dependent single-stranded DNA (ssDNA) exonuclease involved in mitochondrial genome maintenance. Has preference for 5'-3' exonuclease activity but is also capable of endoduclease activity on linear substrates. Necessary for maintenance of proper 7S DNA levels. Probably involved in mitochondrial DNA (mtDNA) repair, possibly via the processing of displaced DNA containing Okazaki fragments during RNA-primed DNA synthesis on the lagging strand or via processing of DNA flaps during long-patch base excision repair. Specifically binds 5-hydroxymethylcytosine (5hmC)-containing DNA in stem cells

The "MGME1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MGME1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets